Alkermes plc (NASDAQ:ALKS) Shares Purchased by Barclays PLC

Barclays PLC increased its holdings in Alkermes plc (NASDAQ:ALKS) by 108.8% in the third quarter, HoldingsChannel.com reports. The firm owned 423,931 shares of the company’s stock after buying an additional 220,893 shares during the quarter. Barclays PLC’s holdings in Alkermes were worth $11,867,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Centiva Capital LP acquired a new position in shares of Alkermes during the 3rd quarter worth approximately $367,000. Natixis Advisors LLC increased its holdings in Alkermes by 190.3% in the 3rd quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock worth $1,021,000 after acquiring an additional 23,921 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Alkermes during the second quarter worth $1,285,000. Affinity Asset Advisors LLC lifted its holdings in Alkermes by 766.7% during the second quarter. Affinity Asset Advisors LLC now owns 650,000 shares of the company’s stock valued at $15,665,000 after purchasing an additional 575,000 shares in the last quarter. Finally, Van ECK Associates Corp acquired a new stake in shares of Alkermes in the second quarter valued at about $1,807,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ALKS shares. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and upped their price target for the stock from $25.00 to $36.00 in a research report on Tuesday, November 5th. Cantor Fitzgerald decreased their target price on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Mizuho boosted their price target on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective (down from $38.00) on shares of Alkermes in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $35.42.

Alkermes Stock Up 0.0 %

Shares of ALKS opened at $30.51 on Monday. The company’s 50-day moving average price is $28.54 and its 200 day moving average price is $27.02. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $32.88. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The firm has a market cap of $4.94 billion, a P/E ratio of 15.65, a price-to-earnings-growth ratio of 1.03 and a beta of 0.49.

Insider Activity

In related news, SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the transaction, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Craig C. Hopkinson sold 58,996 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the sale, the executive vice president now directly owns 83,300 shares in the company, valued at approximately $2,505,664. The trade was a 41.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 147,738 shares of company stock valued at $4,572,904. Company insiders own 4.89% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.